Samedan Ltd Pharmaceutical Publishers

Archive of previous issues

Subscribe ONLINE

Pharmaceutical Industry Comprehensive Directory

Industry Events Calendar

News and Press Releases

Employment Opportunities

Advertising with us

Air Transport Publications

home > ebr > spring 2003 > where to biomanufacture? one state's efforts to answer the question

PUBLICATIONS

European BioPharmaceutical Review Where to Biomanufacture? One State's Efforts to Answer the Question
Where will your company manufacture its next biopharmaceutical product for the North American market? This is a question that looms large for the biotechnology and pharmaceutical industries because an estimated 1,000 large-molecule drugs are moving through clinical trials and toward the marketplace worldwide, threatening to overwhelm current biomanufacturing capacity. Experts in the industry widely agree there is, and will be for the immediate future, an acute global shortage of capacity to produce these products.
Read full article >>



Rate this article	You must be a member of the site to make a vote.	Average rating:	0

There are no comments in regards to this article.

Post a comment

Read all comments

By Barry D Teater, Director of Corporate Communications at the North Carolina Biotechnology Center

Barry D Teater is in his 17th year with the North Carolina Biotechnology Center, the world's first government-based initiative in biotechnology economic development. He is responsible for the Center's websites, publications, media relations, visitor briefings, trade show exhibits, advertising and related activities.

He holds Bachelor's and Master's degrees in Journalism from Eastern Kentucky University and the University of North Carolina at Chapel Hill, respectively.